Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP199850.RAZ2e_5SLeUfdkyHJxGr2OPzR1j3cg9BOmezhHa-AvlzQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP199850.RAZ2e_5SLeUfdkyHJxGr2OPzR1j3cg9BOmezhHa-AvlzQ130_assertion type Assertion NP199850.RAZ2e_5SLeUfdkyHJxGr2OPzR1j3cg9BOmezhHa-AvlzQ130_head.
- NP199850.RAZ2e_5SLeUfdkyHJxGr2OPzR1j3cg9BOmezhHa-AvlzQ130_assertion description "[However, patients with TOP2A aberrations receiving methotrexate-based therapy exhibited a significant decrease in 5-year distant disease-free survival and breast cancer-specific overall survival, especially for patients with TOP2A deletions (disease-free survival: hazard ratio, 5.31 [P = .001], and breast cancer-specific overall survival: hazard ratio, 6.45 [P ? .001]).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP199850.RAZ2e_5SLeUfdkyHJxGr2OPzR1j3cg9BOmezhHa-AvlzQ130_provenance.
- NP199850.RAZ2e_5SLeUfdkyHJxGr2OPzR1j3cg9BOmezhHa-AvlzQ130_assertion evidence source_evidence_literature NP199850.RAZ2e_5SLeUfdkyHJxGr2OPzR1j3cg9BOmezhHa-AvlzQ130_provenance.
- NP199850.RAZ2e_5SLeUfdkyHJxGr2OPzR1j3cg9BOmezhHa-AvlzQ130_assertion SIO_000772 22204715 NP199850.RAZ2e_5SLeUfdkyHJxGr2OPzR1j3cg9BOmezhHa-AvlzQ130_provenance.
- NP199850.RAZ2e_5SLeUfdkyHJxGr2OPzR1j3cg9BOmezhHa-AvlzQ130_assertion wasDerivedFrom befree-20140225 NP199850.RAZ2e_5SLeUfdkyHJxGr2OPzR1j3cg9BOmezhHa-AvlzQ130_provenance.
- NP199850.RAZ2e_5SLeUfdkyHJxGr2OPzR1j3cg9BOmezhHa-AvlzQ130_assertion wasGeneratedBy ECO_0000203 NP199850.RAZ2e_5SLeUfdkyHJxGr2OPzR1j3cg9BOmezhHa-AvlzQ130_provenance.